Category Archives: Public Policy

Latest From Public Policy

Congress Blog: Medical Advances Keep Me Running

U.S. Capitol Building - Congress

This week, 74-year-old multiple myeloma patient Don Wright shares his story on how cancer drugs have allowed him to not only keep his cancer in check, but enabled him to be well enough and free enough to run marathons around the country. For 12 years, Wright has been battling a cancer called multiple myeloma, a rare cancer in the bone marrow that used to have a life expectancy of just three years. Medical advances changed that. Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post

Register for the 2015 BIO IP & Diagnostics Symposium!

Biotechnology Industry Organization (BIO)

The Third Annual BIO IP & Diagnostics Symposium takes place on September 18, 2015 in Alexandria, Virginia! Have you reserved your seat at the Symposium yet? Space is limited. Register today. The symposium will bring together representatives of academia, government and industry to review the current patent law landscape and evaluate the impact on both the genetic diagnostics and biopharmaceutical sectors. The program will review IP issues for both diagnostics generally and companion diagnostics. It will Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , ,

WSJ: U.S. Concessions on TPP Means Fewer Cures

Seal of the President of the U.S.

Today’s Wall Street Journal editorial, Pacific Trade Brinksmanship, does an outstanding job highlighting the important role that patent protection plays in promoting innovation and fostering medical breakthroughs. The article highlights why adequate protections for biologics must be a centerpiece of a successful Trans-Pacific Partnership (TPP). One of the issues being negotiated is the right amount of patent protection for innovative medicines. As the editorial notes, the U.S. currently wants “biologic protections to last a dozen Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

New Report Suggests RDP Does Not Increase Healthcare Expenditures

health care, medicine

A new paper by the Geneva Network suggests that increasing the period of regulatory data protection (RDP) for biologic medicines would not increase expenditures for medicines. As countries navigate the final negotiations in the Trans-Pacific Partnership, the U.S. and Japan have advocated for increased regulatory data protection for biologic medicines by other TPP countries. In the U.S. biologics enjoy 12 years of data exclusivity; the only TPP countries, aside from the U.S, offering more than Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

225th Anniversary of First U.S. Patent

admin-ajax

225 years ago last Friday the first U.S. patent was issued to Samuel Hopkins for an improved process for creating potash, America’s first industrial chemical compound. America’s Founding Fathers recognized Intellectual property as a fundamental right, so much so they enshrined it into our Constitution. The systems for issuing patents have changed over the years, but Congress retains the authority to regulate and change matters of patent law. Unfortunately, not all changes to patent law Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,